ПОНЕСИМОД (ACT-128800)
Multicenter, Non-comparative Extension of Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03232073/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–65 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 40 чел. в стране «Беларусь».
- Центров в реестре: 5 в 3 городах. Список — ниже на странице.
- Плановая дата окончания (01.2024) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 20
Критерии включения
- Signed informed consent
- Subjects with MS having completed the double-blind treatment in the core study as scheduled
- Compliance with teriflunomide elimination procedure
- Women of childbearing potential (WOCBP) must have a negative pre-treatment urine pregnancy test, must agree to undertake 4-weekly urine pregnancy tests, and must have been using reliable methods of contraception. Fertile male subjects participating in the study must agree to use a condom.
Критерии невключения
- Any of the following cardiovascular conditions on Day 1 pre-dose:
- Resting heart rate (HR) < 50 bpm;
- Presence of second degree atrioventricular (AV) block or third degree AV block or a QTcF interval > 470 ms (females), > 450 ms (males);
- Any of the following alerts from central laboratory at Visit 14 of the core study (EOT) which was confirmed as an alert at repeated testing or not repeated prior to FU1 of the core study:
- Lymphocyte count: < 0.2 x 109/L;
- Neutrophil count <1.0 × 109/L;
- Platelet count < 50 × 109/L;
- Creatinine clearance < 30 mL/min
- At Visit 14 of the core study (EOT) >30% decrease from core study baseline FEV1 and/or FVC;
- Clinically significant, persistent respiratory AEs (e.g., dyspnea) not resolved prior to first dosing in the extension study.
- Macular edema at any time between Visit 1 (Screening) in the core study and Day 1 of the extension study.
- Presence of the following at core study Visit 14 (EOT, Week 108), FU1, or abbreviated visit FU2, or on Day 1 of the extension study pre-dose:
- Suspected opportunistic infection of the CNS or any other infection which, in the opinion of the investigator, contraindicates re-start of the study drug;
- Stevens-Johnson syndrome or toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms.
- Need for and intention to administer forbidden study treatment-concomitant therapy
- Women who are pregnant or lactating.
- Male subjects wishing to parent a child;
- Treatment with any MS Disease Modifying Therapies;
- Any other clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the subject at risk by participating in the study;
- Subjects unlikely to comply with the extension study protocol based on investigator best judgment
Источник: ClinicalTrials.gov, NCT03232073 · запись обновлена в реестре 22 июня 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (10)
- Annualized Confirmed Relapse Rate (ARR) — From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Time From Core Study Randomization to First Confirmed Relapse — From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Time to First 12-week Confirmed Disability Accumulation (CDA) — From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Time to First 24-week Confirmed Disability Accumulation (CDA) — From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Percentage of Participants With Absence of Relapses — From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Change From Baseline in Expanded Disability Status Scale (EDSS) — From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of Study — From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of Study — From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
- Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI) — From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
- Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRI — From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Цель исследования
Задачи исследования в рамках оценки безопасности • оценка безопасности и переносимости понесимода при длительном применении в дозе 20 мг у пациентов с рецидивирующим рассеянным склерозом (РРС). • оценка действия понесимода при возобновлении лечения пациентов с РРС после перерыва. Задачи исследования в рамках оценки эффективности • оценка способности понесимода контролировать течение РРС при длительном применении в дозе 20 мг. • оценка влияния перехода с терифлуномида на понесимод в дозе 20 мг на контроль над течением РРС.
Где проходит
5 центров в 3 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03232073 Официальный реестр (США) · загружено 9 ноября 2026Название, сроки, центры
-
clinmarket · № 12134 Каталог исследований · загружено 1 октября 2026Препарат, номер протокола, цель, разрешение, фаза, статус, число участников, лекарственная форма, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.